Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells
Telomir Pharmaceuticals (NASDAQ:TELO) reported preclinical findings on October 9, 2025 showing Telomir-1 selectively reduces viability of aggressive triple-negative breast cancer (TNBC) cells in dose-dependent laboratory studies. The compound impaired cellular energy and mitochondrial function and caused cell death via an iron-dependent mechanism; cell viability recovered when iron was restored, supporting a defined mechanism linked to Jumonji domain histone demethylases (KDM5A/B, KDM6B). Telomir plans additional cancer models, animal studies, and IND-enabling work. The release notes TNBC represents 10–15% of breast cancers, with metastatic five-year survival around 12–15% and median overall survival ~11–13 months.
Telomir Pharmaceuticals (NASDAQ:TELO) ha riportato risultati preclinici il 9 ottobre 2025 che mostrano che Telomir-1 riduce selettivamente la vitalità delle cellule aggressive del cancro al seno triple-negativo (TNBC) in studi di laboratorio dipendenti dalla dose. Il composto ha compromesso l'energia cellulare e la funzione mitocondriale e ha causato la morte cellulare tramite un meccanismo dipendente dal ferro; la vitalità cellulare è tornata quando il ferro è stato ripristinato, a sostegno di un meccanismo definito legato alle demetilasi delle histone a dominio Jumonji (KDM5A/B, KDM6B). Telomir pianifica ulteriori modelli di cancro, studi su animali e lavori abilitanti l'IND. Il comunicato segnala che il TNBC rappresenta il 10–15% dei tumori al seno, con una sopravvivenza metastatica a cinque anni intorno al 12–15% e una sopravvivenza globale mediana di circa 11–13 mesi.
Telomir Pharmaceuticals (NASDAQ:TELO) ha presentado resultados preclínicos el 9 de octubre de 2025 que muestran que Telomir-1 reduce selectivamente la viabilidad de células agresivas de cáncer de mama triple negativo (TNBC) en estudios de laboratorio dependientes de la dosis. El compuesto alteró la energía celular y la función mitocondrial y causó la muerte celular mediante un mecanismo dependiente del hierro; la viabilidad celular se recuperó cuando se restableció el hierro, respaldando un mecanismo definido ligado a demetilasas de histonas de dominio Jumonji (KDM5A/B, KDM6B). Telomir planea modelos de cáncer adicionales, estudios en animales y trabajo que permita IND. El comunicado señala que el TNBC representa el 10–15% de los cánceres de mama, con una supervivencia metastásica a cinco años alrededor del 12–15% y una supervivencia global media de ~11–13 meses.
Telomir Pharmaceuticals (NASDAQ:TELO)는 2025년 10월 9일 예비 임상 결과를 발표했으며 Telomir-1이 용량 의존적 실험에서 공격적인 삼중 음성 유방암(TNBC) 세포의 생존력을 선택적으로 감소시킨다고 보고했습니다. 화합물은 세포 에너지와 미토콘드리아 기능을 손상시키고 철 의존 기전을 통해 세포 사멸을 유발했습니다; 철이 회복되면 세포 생존력이 회복되어 Jumonji 도메인 히스톤 탈 메틸화효소(KDM5A/B, KDM6B)와 연관된 명확한 기전을 지지합니다. Telomir은 추가 암 모델, 동물 연구 및 IND 허가 작업을 계획합니다. 발표는 TNBC가 유방암의 10–15%를 차지하며 전이성 5년 생존율이 약 12–15%, 중앙생존기간이 약 11–13개월이라고 밝힙니다.
Telomir Pharmaceuticals (NASDAQ:TELO) a présenté des résultats précliniques le 9 octobre 2025 montrant que Telomir-1 réduisait sélectivement la viabilité des cellules agressives du cancer du sein triple négatif (TNBC) dans des études de laboratoire dépendantes de la dose. Le composé a altéré l'énergie cellulaire et la fonction mitochondriale et a provoqué la mort cellulaire via un mécanisme dépendant du fer; la viabilité cellulaire est revenue lorsque le fer a été réintroduit, soutenant un mécanisme défini lié aux déméthylases des histones du domaine Jumonji (KDM5A/B, KDM6B). Telomir prévoit des modèles de cancer supplémentaires, des études animales et des travaux permettant l'IND. Le communiqué indique que le TNBC représente 10–15% des cancers du sein, avec une survie à cinq ans en cas de métastases d'environ 12–15% et une survie globale médiane d'environ 11–13 mois.
Telomir Pharmaceuticals (NASDAQ:TELO) berichtete am 9. Oktober 2025 über präklinische Ergebnisse, die zeigen, dass Telomir-1 die Viabilität aggressiver Triple-negativer Brustkrebszellen (TNBC) in dosisabhängigen Laborstudien selektiv reduziert. Die Verbindung beeinträchtigte die zelluläre Energie und die mitochondriale Funktion und verursachte den Zelltod durch einen eisenabhängigen Mechanismus; die Zellvitalität kehrte zurück, als Eisen wiederhergestellt wurde, was einen definierten Mechanismus unterstützt, der mit Jumonji-Domänen-Histon-Demethylasen (KDM5A/B, KDM6B) verbunden ist. Telomir plant weitere Krebsmodelle, Tierversuche und IND-fähige Arbeiten. In der Mitteilung wird angegeben, dass TNBC 10–15% der Brustkrebsfälle ausmacht, mit einer metastatischen Fünf-Jahres-Überlebensrate von ca. 12–15% und einer medianen Gesamtsüberlebenszeit von ca. 11–13 Monaten.
Telomir Pharmaceuticals (NASDAQ:TELO) ذكرت نتائج قبل السريرية في 9 أكتوبر 2025 تُظهر أن Telomir-1 يقلل بشكل انتقائي من قابلية بقاء خلايا سرطان الثدي الثلاثي السلبية (TNBC) العدوانية في دراسات مخبرية تعتمد على الجرعة. المركّب أضر بالطاقة الخلوية ووظيفة الميتوكوندريا وتسبب بموت الخلية عبر آلية تعتمد على الحديد؛ تعافى البقاء الحيوي للخلية عندما أعيد الحديد، مما يدعم آلية محددة مرتبطة بمزيلات ميثيل هيستونات مجال Jumonji (KDM5A/B, KDM6B). تخطط Telomir لموديلات سرطان إضافية، ودراسات حيوانية، وأعمال تُمكّن IND. يذكر البيان أن TNBC يمثل 10–15% من سرطانات الثدي، مع بقاء على قيد الحياة ميتاستازي لخمس سنوات يقارب 12–15% وبقاء إجمالي متوسط يقارب 11–13 شهراً.
Telomir Pharmaceuticals (NASDAQ:TELO) 于 2025 年 10 月 9 日公布了前临床发现，显示 Telomir-1 在剂量相关的体外研究中选择性地降低了侵袭性三阴性乳腺癌（TNBC）细胞的活性。该化合物削弱了细胞能量与线粒体功能，并通过铁依赖机制引发细胞死亡；当铁被恢复时，细胞活性恢复，支持与 Jumonji 结构域组蛋白去甲基化酶（KDM5A/B, KDM6B）相关的明确机制。Telomir 计划进行更多的癌症模型、动物研究和 IND 使能工作。公告指出 TNBC 占乳腺癌的 10–15%，转移性五年生存率约为 12–15%，中位总生存期约为 11–13 个月。
- Telomir-1 caused dose-dependent TNBC cell viability reduction
- Iron restoration reversed effect, supporting specific mechanism
- Telomir-1 linked to KDM5A/B and KDM6B epigenetic control
- Company plans animal studies and IND-enabling work
- Results are preclinical in vitro only; no reported in vivo data
- No clinical safety or efficacy data; human benefit unproven
Insights
Preclinical data show Telomir-1 selectively impairs TNBC cell viability via iron-dependent mitochondrial and epigenetic mechanisms.
Telomir-1 induced a dose-dependent loss of viability in human triple-negative breast cancer cells and cell death was reversed by reintroducing iron, indicating a direct link between the compound's activity and iron-regulated energy pathways. The release also notes prior evidence that Telomir-1 modulates DNA methylation and specific Jumonji domain histone demethylases (KDM5A/B, KDM6B), offering a plausible mechanistic bridge between epigenetic modulation and disrupted iron/mitochondrial function.
Key dependencies and risks include confirmation beyond in vitro models and demonstration of a therapeutic window in animals; the company plans additional cancer models and animal studies ahead of an IND submission. Concrete near-term items to watch are results from the planned animal studies and any stated IND timeline; the announcement was dated
New findings show Telomir-1 shuts down cellular energy pathways and mitochondrial function in aggressive breast cancer cells, leading to cell death through iron-dependent regulation.
MIAMI, FL, 2654 / ACCESS Newswire / October 9, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing therapies that target epigenetic drivers of cancer, aging, and age-related disease, today announced new findings demonstrating that Telomir-1 significantly decreases the viability of aggressive triple-negative breast cancer (TNBC) cells - a highly invasive form of breast cancer that lacks hormone and HER2 receptors, offers limited treatment options, and carries one of the poorest survival rates among breast cancer subtypes.
In laboratory studies using human triple-negative breast cancer cells, Telomir-1 caused a clear, dose-dependent reduction in cancer cell survival. As concentrations increased, more cancer cells lost their ability to grow and survive. When researchers added iron back to the system, the cells recovered, confirming that Telomir-1's activity depends on regulation of cellular iron and energy balance.
The iron dependency observed in this study is significant because aggressive cancer cells, such as those found in TNBC, are among the most metabolically active of all breast cancer types. These cells depend on iron to support their rapid growth and survival, and iron metabolism contributes directly to this aggressive behavior. By disrupting that iron-driven process, Telomir-1 appears to exploit a core metabolic weakness unique to these tumors. This selectivity is important because normal cells manage iron differently and are less dependent on it, suggesting that Telomir-1 may preferentially affect cancer cells while sparing healthy tissue.
Telomir-1 has previously been shown to reset abnormal DNA methylation patterns and restore balanced gene expression in models of cancer and age-related disease. In TNBC, certain iron-dependent enzymes-known as Jumonji domain histone demethylases (KDMs), including KDM5A/B and KDM6B-are thought to drive gene-expression changes that make cancer cells more aggressive and resistant to therapy. The new findings suggest that Telomir-1's observed effects on energy regulation and iron balance may stem from its ability to influence these same epigenetic mechanisms. Many aggressive cancers show methylation changes that activate pathways controlling iron use, oxidative stress, and energy metabolism. By helping to restore normal epigenetic control, Telomir-1 may indirectly rebalance these pathways, offering new insight into its broader mechanism of action.
"These findings represent an important step forward for Telomir-1 as we work to develop therapies that can meaningfully improve outcomes for patients who currently have very limited choices," said Erez Aminov, Chief Executive Officer of Telomir Pharmaceuticals.
"Functionally, this discovery provides important mechanistic clarity," said Dr. Angel, Chief Scientific Advisor of Telomir Pharmaceuticals. "The reversal of the effect by iron, together with the established effects on KDMs, confirms that Telomir-1 acts as a key regulator through now-identified biological pathways rather than through nonspecific toxicity. This unique profile-targeting a defined metabolic weakness in cancer cells-is precisely the kind of mechanism that can support both efficacy and safety in future studies."
Telomir plans to expand these findings by testing additional cancer types, including pancreatic and leukemia models, and conducting further animal studies in preparation for its Investigational New Drug (IND) submission.
The Unmet Need in Triple-Negative Breast Cancer
Triple-negative breast cancer accounts for roughly 10
Despite recent progress, outcomes remain poor: the five-year survival rate for patients with metastatic TNBC is only around 12
With approximately 30,000-45,000 new TNBC cases diagnosed each year in the United States and several hundred thousand globally, the market opportunity for an effective therapy remains significant and unmet.
About Telomir Pharmaceuticals
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a preclinical-stage biotechnology company developing small-molecule therapies that target the root causes of cancer, aging, and age-related diseases by resetting dysregulated epigenetic programs. The Company's lead candidate, Telomir-1, is being advanced across oncology and longevity indications based on its differentiated ability to restore tumor suppressors, block undruggable enzymes, and reprogram gene control. For more information, visit www.telomirpharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release, statements of Telomir's management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.
Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at www.sec.gov. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact Information
Helga Moya
info@telomirpharma.com
(786) 396-6723
SOURCE: Telomir Pharmaceuticals, Inc
View the original press release on ACCESS Newswire
FAQ
What did Telomir announce about Telomir-1 on October 9, 2025 for TNBC (TELO)?
How did researchers confirm Telomir-1’s mechanism in the TELO study?
Does the October 9, 2025 TELO announcement include clinical or animal data?
What is the unmet need highlighted for TNBC in the TELO release?
Will Telomir-1 move toward human testing after this TELO update?
